ONS - Oncobiologics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.855
-0.045 (-5.00%)
As of 12:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.900
Open0.900
Bid0.855 x 800
Ask0.900 x 900
Day's Range0.855 - 0.900
52 Week Range0.775 - 1.700
Volume2,105
Avg. Volume28,190
Market Cap61.73M
Beta0.24
PE Ratio (TTM)N/A
EPS (TTM)-1.561
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Oncobiologics Provides Business Update and Reports Third Quarter Financial Results for Fiscal 2018

    CRANBURY, N.J., Aug. 14, 2018-- Oncobiologics, Inc. today reported financial results and business highlights for its three and nine months ended June 30, 2018.. Continued to prepare ONS-5010 for clinical ...

  • GlobeNewswire2 months ago

    Oncobiologics Appoints Lawrence A. Kenyon as President and CEO

    Oncobiologics, Inc. (ONS) today announced that Lawrence A. Kenyon, its Chief Financial Officer (CFO) and Corporate Secretary, has been appointed to the role of President and Chief Executive Officer (CEO), and has joined the Company’s Board of Directors as a Class II Director. Mr. Kenyon will remain as CFO until a replacement is appointed.

  • GlobeNewswire2 months ago

    Oncobiologics Completes Exchange of Series A Convertible Preferred Stock for Newly Created Series A-1 Convertible Preferred Stock

    CRANBURY, N.J., July 19, 2018-- Oncobiologics, Inc. today announced that, on July 18, 2018, the Company completed the exchange of an aggregate of 58,735 shares of voting Series A Convertible Preferred ...

  • GlobeNewswire2 months ago

    Oncobiologics Regains Compliance with Applicable Nasdaq Listing Requirements

    Oncobiologics, Inc. (ONS) today announced that, on July 10, 2018, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with the applicable requirements for the continued listing of the Company’s securities on The Nasdaq Capital Market, including the minimum $35 million market value of listed securities requirement. Accordingly, the Company’s previously disclosed matter before the Nasdaq Hearings Panel has been closed. The Company remains subject to a 180-day grace period, through October 23, 2018, to regain compliance with Nasdaq’s minimum $1.00 per share bid price requirement for continued listing.

  • ACCESSWIRE4 months ago

    Blog Exposure - Evogene Signs Collaboration Agreement with BASF for Development of Novel Insecticides

    LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want access to our free research report on Evogene Ltd (NASDAQ: EVGN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EVGN as the Company's latest news hit the wire. On May 29, 2018, the Company, which is a leading biotechnology organization developing novel products for life science markets, and BASF, which is one of the world's leading chemical Companies, declared on May 29, 2018, that they have signed a new collaboration agreement for the development of novel insecticides based on new binding areas (Site-of-Action or ‘SoA') on key insecticidal target proteins. Active-Investors.com is currently working on the research report for Oncobiologics, Inc. (NASDAQ: ONS), which also belongs to the Healthcare sector as the Company Evogene.

  • Why Oncobiologics Inc’s (NASDAQ:ONS) Ownership Structure Is Important
    Simply Wall St.5 months ago

    Why Oncobiologics Inc’s (NASDAQ:ONS) Ownership Structure Is Important

    In this analysis, my focus will be on developing a perspective on Oncobiologics Inc’s (NASDAQ:ONS) latest ownership structure, a less discussed, but important factor. A company’s ownership structure is oftenRead More...

  • Is Oncobiologics Inc (NASDAQ:ONS) Excessively Paying Its CEO?
    Simply Wall St.6 months ago

    Is Oncobiologics Inc (NASDAQ:ONS) Excessively Paying Its CEO?

    Leading Oncobiologics Inc (NASDAQ:ONS) as the CEO, Pankaj Mohan took the company to a valuation of US$23.68M. Understanding how CEOs are incentivised to run and grow their company is anRead More...

  • Want To Invest In Oncobiologics Inc (NASDAQ:ONS)? Here’s How It Performed Lately
    Simply Wall St.7 months ago

    Want To Invest In Oncobiologics Inc (NASDAQ:ONS)? Here’s How It Performed Lately

    For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Oncobiologics Inc’s (NASDAQ:ONS) track record on a high level, to giveRead More...

  • What You Must Know About Oncobiologics Inc’s (NASDAQ:ONS) Major Investors
    Simply Wall St.7 months ago

    What You Must Know About Oncobiologics Inc’s (NASDAQ:ONS) Major Investors

    In this article, I will take a quick look at Oncobiologics Inc’s (NASDAQ:ONS) recent ownership structure – an unconventional investing subject, but an important one. When it comes to ownershipRead More...

  • Is Oncobiologics Inc’s (NASDAQ:ONS) CEO Paid Enough To Stay Motivated?
    Simply Wall St.9 months ago

    Is Oncobiologics Inc’s (NASDAQ:ONS) CEO Paid Enough To Stay Motivated?

    Pankaj Mohan took the helm as Oncobiologics Inc’s (NASDAQ:ONS) CEO and grew market cap to USD$29.68M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial part ofRead More...

  • Does Oncobiologics Inc’s (ONS) Recent Track Record Look Strong?
    Simply Wall St.10 months ago

    Does Oncobiologics Inc’s (ONS) Recent Track Record Look Strong?

    For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.Read More...

  • Is Oncobiologics Inc (ONS) Thriving Or Barely Surviving In The Healthcare Sector?
    Simply Wall St.10 months ago

    Is Oncobiologics Inc (ONS) Thriving Or Barely Surviving In The Healthcare Sector?

    Oncobiologics Inc (NASDAQ:ONS), a USD$34.16M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and the growingRead More...